



Division de gastro-entérologie
Division of Gastroenterology

Dr. A. Bitton

Directeur
Director

Dr. W. Afif

Directeur de site, HGM
Site Director, MGH

Dr. V. Baffis

Dr. A. Barkun

Directeur endoscopie
thérapeutique et directeur
de l'évaluation de la qualité,
CUSM

Director, Bilio-Pancreatic
Endoscopy and Chief Quality
Officer, MUHC

Dr. T. Bessissow

Dr. P. Cleland

Dr. M. Deschênes

Directeur de l'hépatologie, CUSM
Hepatology Director, MUHC

Dr. C. A. Fallone

President, Association des médecins
du département, CUSM
Chair, Departmental Association
of Physicians, MUHC

Dr. P. Ghali

Directeur de site, HRV
Site Director, RVH

Dr. S. Mayrand

Directeur, Finances
Financial Director

Dr. S. Mishkin

Dr. P. Lakatos

Directeur, Centre MII, CUSM
Director, MUHC IBD Centre

Dr. J. Parent

Dr. G. Sebastiani

Dr. E. Seidman

Titulaire de la chaire en MII
et directeur de la recherche
McGill Chair in IBD and Director
of G.I. Research

Dr. M. Sewitch

Directrice de la recherche en santé
des populations, CUSM
Director, Population Health Research
MUHC

Dr. C. Soulellis

Directeur de programme
de résidence, Université McGill
Residency Program Director
McGill University

Dr. P.L. Szego

Dr. K. Waschke

Directeur de l'endoscopie, CUSM
Endoscopy Director, MUHC

Dr. G. Wild

Dr. P. Wong

Hôpital général de Montréal
Montreal General Hospital
C7-200 - 1650 Cedar
Montréal QC H3G 1A4
Canada

Tel 514 934-8308

Fax 514 934-8531

Hôpital Royal Victoria, site Glen
Royal Victoria Hospital, Glen site
D05.7150 - 1001 boul Décarie
Montréal QC H4A 3J1
CANADA

Tel 514 843-1616

Fax 514 843-1421

cusm.ca muhc.ca

May 6th 2021

Response to reviewers

Dear Editor(s),

Hereby, we submit our revised manuscript entitled "Therapeutic drug monitoring in inflammatory bowel disease: the dawn of reactive monitoring" as an original article to the World Journal of Gastroenterology.

Please find below our detailed responses to the reviewers' comments:

Reviewer #1, Number ID: 05997207

"Title. Does the title reflect the main subject/hypothesis of the manuscript? The title seems to be not in line with the review's conclusions: reactive TDM remains the most robust application because there is no evidence that the proactive approach is beneficial. Thus we do not think it is appropriate to talk about "the dawn of reactive monitoring." Key words: biological therapies I suggest little changes in the text underlined as commentaries in the file attached"

Conclusion: Accept (General priority)

Scientific Quality: Grade B (Very good)

Language Quality: Grade A (Priority publishing)

We thank the reviewers for their evaluations and comments.

We, as a group, reviewed the comments made and discussed the suitability of the title for this review article and we feel that it reflects the contents of the review and therefore would like to keep it as it is.

We also modified the key words as recommended and carried out the recommended changes suggested in the text.



We hope that our responses are adequate to further clarify and improve our study and we thank the reviewers for their comments.

Thank you for your time and consideration.

Best regards,

A handwritten signature in blue ink, appearing to read 'Peter Lakatos'.

Peter LAKATOS, MD, DSc, FEBG, AGAF
Associate Editor
World J Gastroenterology

Director of IBD Centre, Professor,
McGill University, MUHC, Montreal General Hospital,
1650 Ave. Cedar, D16.173.1, Montreal, QC, H3G 1A4
Tel: [+1-514-9341934](tel:+15149341934) x ext 45567
Fax: +1-514-934-4452
Tel: [+1-514-4317994](tel:+15144317994)
e-mail: Peter.Lakatos@muhc.mcgill.ca
e-mail: peter.lakatos@mcgill.ca
email: kislakpet99@gmail.com